Results 11 to 20 of about 2,653,331 (305)

Antiviral therapy: a perspective

Drug Design, Development and Therapy, 2016
This paper discusses extracorporeal removal of viral particles and their antigens from the blood as an auxiliary therapy. This hypothesis has not been reported before. In some chronic blood-borne viral infections, the virus remains systemic and persistent for extended periods of time, with adverse effects that weaken the immune system.
Shahidi Bonjar AH
openaire   +6 more sources

Cyclodextrins in the antiviral therapy

Journal of Drug Delivery Science and Technology, 2021
The main antiviral drug-cyclodextrin interactions, changes in physicochemical and physiological properties of the most commonly used virucides are summarized. The potential complexation of antiviral molecules against the SARS-Cov2 also pointed out the lack of detailed information in designing effective and general medicines against viral infections ...
Jicsinszky L., Martina K., Cravotto G.
openaire   +2 more sources

Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism [PDF]

, 2003
Background. Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of chronic active hepatitis C. Polymorphisms in the promoter region of the TNF-alpha gene can alter the TNF-alpha expression and modify the host immune response.
Konig, A., Folwaczny, Christian, Schmidt, F., Simperl, C., Schaefer, M., Torok, P., Glas, J., Schiemann, Uwe, Martin, K.   +8 more
core   +1 more source

ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells

Scientific Reports, 2017
Management of infection with hepatitis B virus (HBV) remains a global health problem. Persistence of stable covalently closed circular DNA (cccDNA) during HBV replication is responsible for modest curative efficacy of currently licensed drugs. Novel gene
Tristan Scott, Buhle Moyo, Samantha Nicholson, Mohube Betty Maepa, Koichi Watashi, Abdullah Ely, Marc S. Weinberg, Patrick Arbuthnot   +7 more
doaj   +1 more source

Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study

Antiviral Therapy, 2022
Background Tenofovir alafenamide (TAF) is a new anti-hepatitis B virus nucleotide analogue that can cause dyslipidaemia in AIDS patients, but the effect of TAF on blood lipids in patients with chronic hepatitis B (CHB) is unknown.
Yeqiong Zhang, Zhipeng Li, Qiumin Luo, Wenxiong Xu, Lu Wang, Shu Zhu, Liang Peng, Chan Xie   +7 more
doaj   +1 more source

Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic Hepatitis B virus infected patients [PDF]

, 2012
Natural killer (NK) cells play a critical role in innate antiviral immunity, but little is known about the impact of antiviral therapy on the frequency of NK cell subsets.
Xiumei Chi, Lv, J., Yu Pan, Zhigang Tian, Niu, J., Juan Lv, Weihua Xiao, Yan, H., Xu, D., Zhengkun Tu, Hu, X., Chi, X., Junqi Niu, Qinglong Jin, Xiao, W., Sun, H., Hou, J., Jinlin Hou, Hongqing Yan, Haibo Sun, Tian, Z., Tu, Z., Xiaoli Hu, Jin, Q., Pan, Y., Damo Xu   +25 more
core   +1 more source

A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir

Antiviral Therapy, 2022
Ergotism is a rare cause of peripheral vasoconstriction with varying presentation depending on the affected vessels. Coronary vasospasm is a rare, potentially fatal manifestation of ergotism.
Cheng-En Wu, Chun-Hsien Wu, Shih-Hung Tsai, Wen-I Liao   +3 more
doaj   +1 more source

HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective

Antiviral Therapy, 2023
Contemporary antiretroviral therapy (ART) regimens have high barriers to the development of drug resistance. However, resistance to earlier antiretrovirals and uncommon cases of resistance to contemporary ART illustrate the continued need for good ...
Andrew Carr, Nicola E Mackie, Roger Paredes, Kiat Ruxrungtham   +3 more
doaj   +1 more source

A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection

Antiviral Therapy, 2022
Background The GSK3732394 multivalent protein was developed as a novel, long-acting, antiretroviral biologic treatment regimen with three independent, non–cross-resistant mechanisms for inhibiting HIV-1 entry.
Mark Krystal, Shiven Chabria, Daren Austin, Allen Wolstenholme, David Wensel, Max Lataillade, Judah Abberbock, Mark Baker, Peter Ackerman   +8 more
doaj   +1 more source

Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives

Antiviral Therapy, 2023
In endemic areas, hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfection is common, and patients with coinfection have a higher risk of developing liver disease such as hepatocellular carcinoma, liver fibrosis and cirrhosis.
Quratulain Maqsood, Aleena Sumrin, Maryam Iqbal, Saima Younas, Nazim Hussain, Muhammada Mahnoor, Abdul Wajid   +6 more
doaj   +1 more source